Friday, 16 Nov 2018

You are here

Rheumatologists are Slow to Change DMARDs

The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment.  Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months. 

Using a prospective RA cohort from the University of Pittsburg (RACER), researchers studied 538 RA patients (with 943.5 patient-years of follow-up) the found that patients in MHDAS had the following delays in DMARD adjustments:

  • 90 days: 60% of MHDAS had their DMARDs changed by 90 days
  • 154 days: Median time to adjust DMARDs in MHDAS patients
  • 301 days: Median time to achieve LDAS in MHDAS patients

Longer delays in DMARD adjustment were more likely in the elderly, lower baseline disease activity scores, longer duration of RA, and those on biologics.

Longer times to achieve LDAS was more likely in African-Americans, those with higher baseline disease activity or those not adjusting DMARD therapy within 90 days.

Such findings are not new or novel as other registries and observational cohorts have also shown therapeutic hesitancy amongst rheumatologists. Harrison et al studied 9873 RA patients in the RADIUS database. Despite having moderate activity (> 5 TJC/SJC), the percentage with no DMARD change was 67% at 6 mos., 48% at 12 mos. and 38% at 18 mos. More than half of patients (54%) did not achieve Pain VAS < 3/10 (https://buff.ly/2yx9A4d). Another prospective RA cohort study of 568 RA patients showed that 377 had severe disease and DMARD changes were variably and slowly made at 3 mos. (44%), 6 mos. (50%) or 12 mos. (68%). (https://buff.ly/2x8yt4Y)

The timeliness of DMARD adjustments in RA is a major unmet need for which many factors need to be addressed. These include the use of adjunctive therapies, treat-to-target metrics, access to care, frequency of patient evaluations and the current lack of time limits on therapeutic decision-making. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CIRT Trial - Methotrexate Fails at Cardiovascular Prevention

Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.

ACR 2018 Podcast - Day 3

Audio Highlights and Interviews from Day 3 at the ACR 2018 meeting  LISTEN HERE

ACR 2018 - Day 3 Report

Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included:

The PEXIVAS Study –  2x2 Trial of Plasma Exchange and Reduced Steroids in ANCA-Associated Vasculitis (AAV) - Abstract #2788

ACR 2018 Podcast - Day 2B

Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTEN HERE

ACR 2018 Podcast - Day 1B

Audio Highlights and Interviews from Day 1 at the ACR 2018 meeting - LISTEN HERE